Puma Biotechnology Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Puma Biotechnology.

Key information

-49.5%

Earnings growth rate

-56.4%

EPS growth rate

Biotechs earnings growth	22.4%
Revenue growth rate	2.2%
Future return on equity	n/a
Analyst coverage	Low
Last updated	06 May 2023

Recent future growth updates

Puma Biotechnology, Inc. (NASDAQ:PBYI) Held Back By Insufficient Growth Even After Shares Climb 34%

Apr 17

Recent updates

Puma Biotechnology, Inc. (NASDAQ:PBYI) Held Back By Insufficient Growth Even After Shares Climb 34%

Apr 17

We Think Puma Biotechnology (NASDAQ:PBYI) Can Stay On Top Of Its Debt

Dec 14

Puma Biotechnology, Takeda enter licensing agreement for cancer treatment alisertib

Sep 20

Puma Bio reports data from mid-stage study of neratinib in EGFR exon 18-mutant NSCLC patients

Jun 04

Puma Biotechnology (NASDAQ:PBYI) Has A Somewhat Strained Balance Sheet

Jun 04

Puma Biotech Struggles To Find Its Footing In Crowded Oncology Space

Apr 26

Analysts Expect Breakeven For Puma Biotechnology, Inc. (NASDAQ:PBYI) Before Long

Apr 12

Puma Biotechnology's(NASDAQ:PBYI) Share Price Is Down 87% Over The Past Three Years.

Mar 08

Are Investors Undervaluing Puma Biotechnology, Inc. (NASDAQ:PBYI) By 49%?

Feb 05

Don't Ignore The Fact That This Insider Just Sold Some Shares In Puma Biotechnology, Inc. (NASDAQ:PBYI)

Jan 10

Puma Biotechnology: Waiting For Commercial Numbers To Catch Up To Clinical Data

Dec 29

A Quick Analysis On Puma Biotechnology's (NASDAQ:PBYI) CEO Compensation

Dec 28

Puma Biotech's neratinib shows improved CNS outcomes in late-stage breast cancer study

Dec 11

Earnings and Revenue Growth Forecasts

NasdaqGS:PBYI - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2025	245	9	66	52	2
12/31/2024	239	11	61	37	3
12/31/2023	231	18	49	30	3
3/31/2020	224	-82	27	27	N/A
12/31/2019	272	-76	22	22	N/A
9/30/2019	280	-95	28	28	N/A
6/30/2019	287	-92	28	28	N/A
3/31/2019	284	-99	-35	-34	N/A
12/31/2018	251	-114	-25	-24	N/A
9/30/2018	202	-147	-117	-67	N/A
6/30/2018	145	-210	-165	-114	N/A
3/31/2018	94	-243	-193	-143	N/A
12/31/2017	28	-292	-223	-172	N/A
9/30/2017	6	-301	-179	-178	N/A
6/30/2017	N/A	-289	-159	-158	N/A
3/31/2017	N/A	-278	-150	-143	N/A
12/31/2016	N/A	-276	N/A	-142	N/A
9/30/2016	N/A	-265	N/A	-134	N/A
6/30/2016	N/A	-260	N/A	-136	N/A
3/31/2016	N/A	-258	N/A	-139	N/A
12/31/2015	N/A	-239	N/A	-154	N/A
9/30/2015	N/A	-225	N/A	-140	N/A
6/30/2015	N/A	-200	N/A	-127	N/A
3/31/2015	N/A	-175	N/A	-110	N/A
12/31/2014	N/A	-142	N/A	-77	N/A
9/30/2014	N/A	-110	N/A	-72	N/A
6/30/2014	N/A	-89	N/A	-60	N/A
3/31/2014	N/A	-63	N/A	-54	N/A
12/31/2013	N/A	-55	N/A	-55	N/A
9/30/2013	N/A	-61	N/A	-66	N/A
6/30/2013	N/A	-72	N/A	-62	N/A
3/31/2013	N/A	-74	N/A	-60	N/A
12/31/2012	N/A	-74	N/A	-44	N/A
9/30/2012	N/A	-62	N/A	-21	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: PBYI's earnings are forecast to decline over the next 3 years (-49.5% per year).

Earnings vs Market: PBYI's earnings are forecast to decline over the next 3 years (-49.5% per year).

High Growth Earnings: PBYI's earnings are forecast to decline over the next 3 years.

Revenue vs Market: PBYI's revenue (2.2% per year) is forecast to grow slower than the US market (7.9% per year).

High Growth Revenue: PBYI's revenue (2.2% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if PBYI's Return on Equity is forecast to be high in 3 years time

Discover growth companies

High growth companies in the Pharmaceuticals & Biotech industry.

Puma Biotechnology Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Consensus EPS estimates increase by 32%, revenue downgraded

Puma Biotechnology, Inc. Provides Earnings Guidance for the Second Quarter and Full Year 2023

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Puma Biotechnology, Inc. (NASDAQ:PBYI) Held Back By Insufficient Growth Even After Shares Climb 34%

Consensus EPS estimates increase by 240%

Full year 2022 earnings released: EPS: US$0 (vs US$0.72 loss in FY 2021)

Recent updates

Investor sentiment improves as stock rises 16%

Consensus EPS estimates increase by 32%, revenue downgraded

Investor sentiment improves as stock rises 17%

Puma Biotechnology, Inc. Provides Earnings Guidance for the Second Quarter and Full Year 2023

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Puma Biotechnology, Inc. (NASDAQ:PBYI) Held Back By Insufficient Growth Even After Shares Climb 34%

Consensus EPS estimates increase by 240%

Full year 2022 earnings released: EPS: US$0 (vs US$0.72 loss in FY 2021)

Puma Biotechnology, Inc. to Report Q4, 2022 Results on Mar 02, 2023

Puma Biotechnology, Inc.’s NERLYNX® Included in NCCN Clinical Practice Guidelines for the Treatment of Breast Cancer with a HER2 Mutation

Founder recently sold US$114k worth of stock

Founder notifies of intention to sell stock

Investor sentiment deteriorated over the past week

Puma Biotechnology, Inc. announced that it has received $2.499996 million in funding

We Think Puma Biotechnology (NASDAQ:PBYI) Can Stay On Top Of Its Debt

Investor sentiment improved over the past week

Puma Biotechnology Presents Updated Findings from the TBCRC-022 Trial at the 2022 San Antonio Breast Cancer Symposium

Investor sentiment improved over the past week

Price target decreased to US$5.40

Puma Biotechnology, Inc. Announces Update on Defamation Lawsuit

Investor sentiment improved over the past week

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Forecast to breakeven in 2024

Puma Biotechnology, Inc. Revises Earnings Guidance for the Full Year 2022

Consensus forecasts updated

Forecast breakeven date moved forward to 2023

Consensus forecasts updated

Puma Biotechnology, Inc. Reiterates Earnings Guidance for the Fiscal Year 2022

Puma Biotechnology, Takeda enter licensing agreement for cancer treatment alisertib

Puma Biotechnology Presents Updated Findings from the Phase II SUMMIT Basket Trial of Neratinib for HER2-Mutant, Recurrent/Metastatic Cervical Cancer at the ESMO Congress 2022

Puma Biotechnology (NASDAQ:PBYI) Takes On Some Risk With Its Use Of Debt

Consensus forecasts updated

Independent Director recently sold US$89k worth of stock

Price target decreased to US$5.40

Price target decreased to US$5.40

Second quarter 2022 earnings released: EPS: US$0.21 (vs US$0.13 loss in 2Q 2021)

Puma Biotechnology Non-GAAP EPS of $0.28, revenue of $59.5M

Puma Biotechnology, Inc. Appoints Alessandra Cesano to Its Board of Directors

Puma Biotechnology, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Founder recently sold US$69k worth of stock

Puma Biotechnology, Inc.(NasdaqGS:PBYI) dropped from Russell 2000 Dynamic Index

Puma Biotechnology Presents Final Results from the Biliary Tract Cohort of the Phase 2 SUMMIT ‘Basket’ Trial of Neratinib at the ASCO 2022 Annual Meeting

Is Puma Biotechnology (NASDAQ:PBYI) Using Debt Sensibly?

Forecast breakeven date moved forward to 2022

Price target increased to US$8.25

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Puma Biotechnology, Inc., Annual General Meeting, Jun 14, 2022

Forecast breakeven date pushed back to 2024

Independent Director recently sold US$72k worth of stock

Puma Bio: Still Worthy Of Consideration After Earnings Surprise

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Puma Biotechnology, Inc. to Report Q4, 2021 Results on Mar 03, 2022

Puma Biotechnology’s NERLYNX® Included in Two Important NCCN Clinical Practice Guideline Updates for the Treatment of Breast Cancer

Robbins Geller Rudman & Dowd LLP Announces Regarding the Puma Biotechnology, Inc. Securities Settlement

Founder notifies of intention to sell stock

Puma Biotechnology, Inc. Presents Updates from the Summit Trial At the 2021 Sabcs Annual Meeting

Price target decreased to US$7.83

Third quarter 2021 earnings released: US$1.10 loss per share (vs US$0.79 loss in 3Q 2020)

Price target decreased to US$8.67

Forecast to breakeven in 2021

Puma Bio: Recent Sell-Off Brings My Position Out Of Mothball

Second quarter 2021 earnings released: US$0.13 loss per share (vs US$0.086 profit in 2Q 2020)

Price target decreased to US$9.38

Forecast breakeven pushed back to 2023

Consensus forecasts updated

FDA Approves Dose Escalation Label Update for Puma Biotechnology’s NERLYNX® (neratinib) in HER2-Positive Early Stage and Metastatic Breast Cancer

Independent Director Hugh O’Dowd has left the company

Independent Director recently sold US$147k worth of stock

Puma Biotechnology Presents Data from the EGFR Exon 18-mutant NSCLC Cohort of the Phase II SUMMIT Trial at the 2021 ASCO Annual Meeting